Journal ID : CJOHNS-23-06-2024-11460
[This article belongs to Volume - 55, Issue - 06]

Title : THE ROLE OF MICRONIZED PROGESTERONE IN THE PREVENTION OF PRETERM BIRTH IN WOMEN WITH CERVICAL LENGTH GREATER THAN 2.5CM

Abstract :

The primary goal of the research is to determine micronized progesterone helps women whose cervical length is longer than 2.5 cm avoid preterm birth. A 2024 cross-sectional study involved 88 female patients with singleton gestation, cervical length exceeding 2.5 cm, and no preterm delivery experience. Participants were assigned to either a case group receiving micronized progesterone or a placebo group. Throughout pregnancy, they were assessed for cervical length, maternal consequences, and neonatal outcomes. Statistical analysis was performed using SPSS version 26.0. A study involving 88 women found that micronized progesterone supplementation significantly reduced preterm birth rates. The control group had a 15% premature birth rate, while the case group had an 8% rate. Adverse events like headache and nausea were common, but no safety problems were found. A subgroup analysis showed that the micronized progesterone group had an ongoing pattern of lower preterm birth rates across various cervical lengths, with women with 2.5 cm cervical lengths showing the most impact. The current study found that in women who are deemed to be extremely susceptible to premature delivery and have a background in preterm deliveries because of unidentified causes, progesterone medication may be beneficial. It is determined that supplementing with micronized progesterone in women whose cervical length is 2.5 cm or shorter has the potential to lower the incidence of premature births. Its viability in standard prenatal treatment is supported by the efficacy characteristics and compliance. This investigation advocates for a fundamental change in risk estimation and personalized measures, providing insightful information on measures to avoid premature births.

Full article